People's Journal of Scientific Research
Published June 1, 2014 | Version v1
Journal article Open

Biology of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Osteoprotegerin (OPG) in Periodontal Health and Disease - A Review

Authors/Creators

  • 1. Department of Periodontology, HKES's S. Nijalingappa Institute of Dental Sciences and Research, Sedam Road, Gulbarga - 585105

Description

Periodontitis is a destructive disease that targets tooth-supporting structures through complex and multifactorial pathogenic processes. Alveolar bone destruction, a hallmark of periodontitis progression and one of the major causes of tooth loss in human, is mediated by the host immune and inflammatory response to microbial challenge. The discovery of the receptor activator of nuclear factor-kappa B (RANK)/ RANK ligand (RANKL)/osteoprotegerin (OPG) axis has improved the knowledge of bone metabolism regulation. The RANKL/RANK interaction is needed for differentiation and maturation of osteoclast precursor cells to activate osteoclasts and for the survival of mature osteoclasts. Osteoprotegerin is the naturally occurring inhibitor of osteoclast differentiation. It binds to RANKL with high affinity and blocks RANKL from interacting with RANK. The RANKL/OPG ratio is increased in periodontitis compared to healthy individuals, suggesting that this molecular interaction may be important in modulating local bone loss. In recent decades, studies on cellular and molecular mechanisms of bone loss in periodontitis have suggested that the use of host modulation agents is an important adjunctive therapy to scaling and root planning. This line of investigation is expected to help in the development of new therapeutic approaches to stop progressive bone resorption induced by oral bacterial challenge.

Files

14. Dr. Veena Patil.pdf

Files (65.3 kB)

Name Size Download all
md5:6e4182ab7fc7398ea648000510a33221
65.3 kB Preview Download

Additional details

References

  • 1. Teitelbaum SL, Ross FR: Genetic regulation of osteoclast development and function. Nat Rev Genet, 2003;4(8): 638-649.
  • 2. Kanzaki H, Chiba M, Shimizu Y, Mitani H: Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. J Dent Res, 2001;80(3):887-891.
  • 3. Nagasawa T, Kiji M, Yashiro R, Hormdee D, Lu H, Kunze M, Sud T, Kosby G, Kobayoshi H, Oda S, Natta H, Ishikawa I: Roles of receptor activator of nuclear factorkappaB ligand (RANKL) and osteoprotegerin in periodontal health and disease. Periodontol, 2000; 2007: 43:65-84.
  • 4. Cochran DL: Inflammation and bone loss in periodontal disease. J Periodontol, 2008;79(8suppl.):1569-1576.
  • 5. Karsenty G, Wagner EF: Reaching a genetic and molecular understanding of skeletal development. Dev Cell, 2002; 2(4):389-406.
  • 6. Rodan GA, Martin TJ: Role of osteoblasts in hormonal control of bone resorption- A hypothesis. Calcif Tissue Int, 1981;33(4):349-351
  • 7. Ikeda T, Kasai M, Utsuyama M, Hirokawa K: Determination of three isoforms of the receptor activator of nuclear factorkappa B ligand and their differential expression in bone and thymus. Endocrinology, 2001;142(4):1419-1426.
  • 8. Suzuki J, Ikeda T, Kuroyama H, Seki S, Kasai M, Utsuyama M, Tastumi M, Uematsu H, Hirakawa K: Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells. Biochem Biophys Res Commun, 2004;314(4):1021-1027
  • 9. Hikita A, Yana 1, Wakeyama H, Nakamura M, Kadono Y, Oshima Y, Nakamura K, Seiki M, Tanaka S: Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappa B ligand. J Biol Chem, 2006;281(48):36846-36855.
  • 10. Wada T, Nakashima T, Hiroshi N, Penninger JM: RANKLRANK signaling in osteoclastogenesis and bone disease. Trends Mol Med, 2006;12(1):17-25.
  • 11. Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS: Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol, 2005;1(1):47-54.
  • 12. Li P, Schwarz EM, O'Keefe RJ, Ma L, Looney RJ, Ritchlin CT, Boyce BF, Xing L: Systemic tumor necrosis factor alpha mediates an increase in peripheral CD1lbhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum, 2004;50(1):265-276.
  • 13. Kollet 0, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, Tesio M, Samstein RM, Goichberg P, Spiegel A, Elson A, Lopidot T: Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med, 2006;12(6):657-664.
  • 14. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully 5, Voura EB, Lacey DL, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell, 2000;103:41-50
  • 15. Kim NS, Kim HJ, Koo BK, Kwon MC, Kim YW, Cho Y, Yokota Y, Penninger JM, Kong YY: Receptor activator of NF-kB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol. 2006;26(3):1002- 1013.
  • 16. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wanger EF, Tamiguchi T: RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 2002;416(6882):744-749.
  • 17. Takayanazi Ogasawara K, Hida S. Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguide T: T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature, 2000;408(6812):600- 605.
  • 18. Kapur RP, Yao Z, Iida MH, Clarke CM, Doggett B, Xing L, Boyce BF: Malignant autosomal recessive osteopetrosis caused by spontaneous mutation of murine RANK. J Bone Miner Res, 2004;19(10):1689-1697.
  • 19. Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, van Hul W, Whyte MP, Nakatsuka K, Hovy L, Anderson DM: Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet, 2000;24(1):45-48.
  • 20. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA, 2004;292(4):490-495
  • 21. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S: Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med, 2002;347(3):175-184.
  • 22. Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love DR, Seidel J, Fawkner M, Banovic T, Callon KE, Grey AB, Reid IR, Middleton-Hardie CA, Cornish J: A mutation in the gene TNFRSF 11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet, 2002,11(18):2119- 2127.
  • 23. Boyce BF, Xing L, Chen D: Osteoprotegerin, the bone protector, is a surprising target for beta-catenin signaling. Cell Metab, 2005;2(9):344-345.
  • 24. Bucay N, Sarosi 1, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev, 1998;12(9):1260-1268.
  • 25. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachelli CM, Rosenfeld ME: Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vase Bio1, 2006;26(9):2117-2124.
  • 26. Collin-Osdoby P: Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res, 2004;95(11):1046-1057.
  • 27. Rogers A, Eastell R: Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab, 2005;90(11):6323-6331.
  • 28. Kawai T, Eisen-Lev R, Seki M, Eastcott JW, Wilson ME, Taubman MA: Requirement of B7 costimulation for Th1- mediated inflammatory bone resorption in experimental periodontal disease. J Immunol, 2000;164(4):2102-2109.
  • 29. Han X, Kawai T, Taubman MA. Interference with immune-cell-mediated bone resorption in periodontal disease. Periodontol , 2000 2007;45:76–94.
  • 30. Sakaguchi S: Regulatory T cells: key controllers of immunologic self-tolerance. Cell, 2000;101(5):455-458.
  • 31. Crotti T, Smith MD, Hirsch R, Soukoulis S, Weedon H, Capone M, Ahern MJ, Haynes D: Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res, 2003;38(4):380-387
  • 32. Wara-aswapati N, Surarit R, Chayasadom A, Boch JA, Pitiphat W: RANKL uregulation associated with periodontitis and porphyromonan gingivalis. J Periodontol, 2007;78(6):1062-1069.
  • 33. Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Töz H, Bordeli A, Atilla G, Mckay IJ, Hughes FJ, Belibasakis GN: Differential expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin mRNA in periodontal diseases. J Periodontal Res, 2007;42(4):287-293.
  • 34. Mogi M, Otogoto J, Ota N, Togari A: Differential Expression of RANKL and Osteoprotegerin in Gingival Crevicular Fluid of Patients with Periodontitis. J Dent Res, 2004;83(2)166-169.
  • 35. Sakellari D, Menti S, Konstantinidis A: Free soluble receptor activator of nuclear factor-kappab ligand in gingival crevicular fluid correlates with distinct pathogens in periodontitis patients. J Clin Periodontol, 2008;35(11):938-943.
  • 36. Teng YT, Nguyen H, Gao X, Kong YY, Gorczynski RM, Singh B, Ellen RP, Pevviinger JM: Functional human Tcell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest, 2000;106(6):59-67.
  • 37. Lin X, Han X, Kawai T, Taubman MA: Antibody to receptor activator of NF-êB ligand ameliorates T cellmediated periodontal bone resorption. Infect Immun, 2011;79(2):911-917.